Includes FDA-cleared Class II IVD FISH Probe Kits for AML and MDS, along with over 150 ASR FISH probes. Custom FISH probes and ancillary products also available.
Discover moreFeaturing the new constitutional NGS platform for cytogenetic research, alongside a broad range of arrays for rare disease and cancer research.
Discover moreChoose from preloaded NGS panels for hematological and solid tumor cancer research or we can help you create your own.
Discover moreThe panel accurately detects SNVs and indels in genes such as CEBPA, JAK2, CALR and MPL, as well as structural variants including FLT3-ITDs and KMT2A-PTDs, and is able to detect low-frequency SNVs and indels with confidence. The figure (right) shows a PTD detection spanning exons 2-8 of the KMT2A gene.
Familial Hypercholesterolaemia (FH) is a genetic condition which results in a high cholesterol level and subsequently leads to a higher risk of early heart disease. OGT is offering an optimised NGS panel which has selected the most relevant genes and SNPs implicated in FH, for your research needs. The figure (left) shows a double deletion on the LDLR gene, as visualised by Interpret software.
The CDKN2A Probe covers CDKN2A (P16) gene and flanking regions, and is labeled in gold. The Centromere 17 Probe covers the chromosome 17 centromere (D17Z1) region and is labeled in aqua. The Centromere 3 Probe covers the chromosome 3 centromere (D3Z1) region and is labeled in red. The Centromere 7 Probe covers the chromosome 7 centromere (D7Z1) region and is labeled in green.
We believe that collaboration is key to improving patient lives. By sharing our knowledge and expertise, we ensure that we move forward with our customers, bound by a collective commitment to unlocking the future of genetic clinical care. See our story.
Enhanced NGS portfolio includes Interpret Software updates and enables rapid and confident variant detection even in difficult-to-sequence regions.
ReadExpansion of access to clinical support network and market-leading genomic solutions aims to improve patient outcomes.
ReadNew leadership will drive OGT’s mission to improve clinical care by partnering with customers.
Read
